154 related articles for article (PubMed ID: 22955008)
1. Prediction of longer-term outcome of treatment-resistant depression in tertiary care.
Fekadu A; Rane LJ; Wooderson SC; Markopoulou K; Poon L; Cleare AJ
Br J Psychiatry; 2012 Nov; 201(5):369-75. PubMed ID: 22955008
[TBL] [Abstract][Full Text] [Related]
2. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
3. Relative effectiveness of tricyclic antidepressant versus monoamine oxidase inhibitor monotherapy for treatment-resistant depression.
Kim T; Xu C; Amsterdam JD
J Affect Disord; 2019 May; 250():199-203. PubMed ID: 30861462
[TBL] [Abstract][Full Text] [Related]
4. N-acetylcysteine augmentation to tranylcypromine in treatment-resistant major depression.
Carvalho AF; Macêdo DS; Goulia P; Hyphantis TN
J Clin Psychopharmacol; 2013 Oct; 33(5):719-20. PubMed ID: 23899640
[No Abstract] [Full Text] [Related]
5. Long-term symptomatic and functional outcome following an intensive inpatient multidisciplinary intervention for treatment-resistant affective disorders.
Wooderson SC; Fekadu A; Markopoulou K; Rane LJ; Poon L; Juruena MF; Strawbridge R; Cleare AJ
J Affect Disord; 2014 Sep; 166():334-42. PubMed ID: 25012450
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
Thomas SJ; Shin M; McInnis MG; Bostwick JR
Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
[TBL] [Abstract][Full Text] [Related]
7. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment.
Schoeyen HK; Kessler U; Andreassen OA; Auestad BH; Bergsholm P; Malt UF; Morken G; Oedegaard KJ; Vaaler A
Am J Psychiatry; 2015 Jan; 172(1):41-51. PubMed ID: 25219389
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of antidepressant-refractory depression: the relevance of unrecognized bipolarity.
Inoue T; Nakagawa S; Kitaichi Y; Izumi T; Tanaka T; Masui T; Kusumi I; Denda K; Koyama T
J Affect Disord; 2006 Oct; 95(1-3):61-7. PubMed ID: 16797078
[TBL] [Abstract][Full Text] [Related]
9. [Combining a classic monoamine oxidase inhibitor with a tricyclic antidepressant in therapy-resistant depression: a case report and literature review].
Schipper P; Vanmolkot L; Peeters FP
Tijdschr Psychiatr; 2016; 58(12):886-890. PubMed ID: 27976787
[TBL] [Abstract][Full Text] [Related]
10. [Lithium augmentation to monoamine oxidase-inhibitors in treatment-resistant depressive disorders: case report and overview of literature].
Gudde A; van der Meij A; Spijker J
Tijdschr Psychiatr; 2019; 61(7):498-503. PubMed ID: 31372971
[TBL] [Abstract][Full Text] [Related]
11. Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study.
Ciudad A; Álvarez E; Roca M; Baca E; Caballero L; García de Polavieja P; Casillas M; Valladares A; Gilaberte I
J Clin Psychiatry; 2012 Feb; 73(2):185-91. PubMed ID: 22053897
[TBL] [Abstract][Full Text] [Related]
12. [MAO-inhibitors--a treatment option for treatment resistant depression: application, efficacy and characteristics].
Köhler S; Stöver LA; Bschor T
Fortschr Neurol Psychiatr; 2014 Apr; 82(4):228-36; quiz 237-8. PubMed ID: 24710679
[No Abstract] [Full Text] [Related]
13. The Dutch Measure for quantification of Treatment Resistance in Depression (DM-TRD): an extension of the Maudsley Staging Method.
Peeters FP; Ruhe HG; Wichers M; Abidi L; Kaub K; van der Lande HJ; Spijker J; Huibers MJ; Schene AH
J Affect Disord; 2016 Nov; 205():365-371. PubMed ID: 27568174
[TBL] [Abstract][Full Text] [Related]
14. The use of MAOIs in primary care.
Culpepper L
J Clin Psychiatry; 2012 May; 73(5):e19. PubMed ID: 22697202
[TBL] [Abstract][Full Text] [Related]
15. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up.
Altshuler L; Suppes T; Black D; Nolen WA; Keck PE; Frye MA; McElroy S; Kupka R; Grunze H; Walden J; Leverich G; Denicoff K; Luckenbaugh D; Post R
Am J Psychiatry; 2003 Jul; 160(7):1252-62. PubMed ID: 12832239
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of monoamine oxidase inhibitor treatment for bipolar depression versus unipolar depression: An exploratory case cohort study.
Kim TT; Amsterdam JD
Acta Psychiatr Scand; 2023 Feb; 147(2):198-204. PubMed ID: 36331516
[TBL] [Abstract][Full Text] [Related]
17. Introduction: a fresh look at monoamine oxidase inhibitors for depression.
Cohen LJ; Sclar DA
J Clin Psychiatry; 2012; 73 Suppl 1():3-4. PubMed ID: 22951235
[No Abstract] [Full Text] [Related]
18. Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up.
Goldberg JF; Harrow M
J Affect Disord; 2004 Aug; 81(2):123-31. PubMed ID: 15306137
[TBL] [Abstract][Full Text] [Related]
19. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study.
Li CT; Bai YM; Huang YL; Chen YS; Chen TJ; Cheng JY; Su TP
Br J Psychiatry; 2012 Jan; 200(1):45-51. PubMed ID: 22016435
[TBL] [Abstract][Full Text] [Related]
20. Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?
Bottemanne H; Bonnard E; Claret A; Petit AC; Gaillard R; Fossati P
J Clin Psychopharmacol; 2020; 40(6):636-638. PubMed ID: 33009225
[No Abstract] [Full Text] [Related]
[Next] [New Search]
